Hamed Javan MD
Jewish General Hospital
Dr Javan is a medical doctor, completed Master of Experimental Medicine-Oncology program at McGill University, and working as clinical/research at the Jewish General Hospital with Dr Petr Kavan and Dr Gerald Batist. Dr Javan has established a phase II clinical trial for pancreatic cancer. He has a high interest toward investigator-initiated studies, and running new study protocols. Currently, he is preparing new studies in phase II, III and IV for Pancreatic and Colorectal Cancer. His particular research interest is: Pre—operative FOLFIRINOX in pancreatic cancer.
Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer
Pancreatic Cancer is a disease with poor prognosis. In 2017, its 5-year net survival rate is only 8% with only 2% in metastatic setting and it is third common cause of cancer related death. Only less than 20% of cases are eligible for surgery at diagnosis, so we tried to evaluate the role preoperative FOLFIRINOX in potentially curable pancreatic cancer in retrospective study and clinical trial.
EVEN MORE SEMINARS
Prantik Das University Hospital of Derby and Burton NHS Foundation Trust
The Changing Landscape of Prostate Radiotherapy
Dr Abeer Shabaan Queen Elizabeth Hospital Birmingham & University of Birmingham
Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations
Dr Penny Kechagioglou GenesisCare UK
Breast cancer Service of the Future: a service transformation
Professor Robert Thomas Bedford and Addenbrooke's Cambridge University Hospitals
Evidence based lifestyle strategies after cancer - a research review
Professor Anthony Howell The University of Manchester / The Christie NHS Foundation Trust
Improving risk estimation of breast cancer